Understanding HTLV Infection and HAM/TSP Disease
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This research study evaluates people with HTLV infection, a virus that can cause a nerve disorder called HAM/TSP. Researchers want to better understand who gets this condition and why, which may help develop future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have tested positive for HTLV-1 infection, or have an uncertain test result, or have been exposed to HTLV through a family member
- You are willing to undergo medical evaluations and procedures as part of the study
- You do not have serious medical, social, or psychiatric conditions that would make study participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether teriflunomide can help people with HTLV-1 associated myelopathy (HAM) or tropical spastic paraparesis (TSP). It also checks safety and how well the treatment can be followed over time.
This study measures how much HIV is in your blood and lymph node tissue. If you qualify, you would also allow blood and other tests (including genetic and hepatitis screening), which may help researchers better understand how HIV affects the body.
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
This study tests whether adding tenofovir (an antiviral medication) to dolutegravir helps treat HTLV-1 infection better than dolutegravir alone. HTLV-1 is a virus that can cause serious health problems, and researchers want to find the most effective treatment combination.
This trial looks at patterns of gene activity (from blood/tissue samples) in adults with spinal tuberculosis. The goal is to better understand the disease and how to tell different conditions apart, which may help future care.
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
Hear when a new HTLV-I Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.